Clinical, Cosmetic and Investigational Dermatology最新文献

{"title":"Defect Size Dependent Reconstruction Strategy of the Nasal Tip Cutaneous Wounds: A Retrospective Study.","authors":"Minliang Wu, Xinyi Zhang, Ang Li, Jianguo Xu, Haiying Dai, Ji Zhu, Jie Dong, Kexin Chen, Yuai Xiao, Yuchong Wang, Chunyu Xue","doi":"10.2147/CCID.S515533","DOIUrl":"10.2147/CCID.S515533","url":null,"abstract":"<p><strong>Objective: </strong>To achieve satisfying function and appearance of nasal tip after tumor resection.</p><p><strong>Methods: </strong>This retrospective study included patients with nasal tip tumors admitted between January 2010 and January 2024. A standardized data collection template was used to collect related variables. Tumors were all resected according to the guidelines, and the defects were repaired with different flaps. For nasal tip soft tissue defects smaller than 1 cm, a horn-shaped flap was used; for defects with a diameter of 1-2 cm, the bilobed flap was applied; for defects larger than 2 cm, frontonasal flap was designed.</p><p><strong>Results: </strong>Twenty-eight patients were included in this study. All the skin defects were repaired according to the one-stage reconstruction strategy. All patients achieved primary healing without severe complications. Slight edema occurred in 5 patients, and slight infection occurred in 2 patients, all healed with dressing change in several days. Ideal aesthetic results achieved without distortion of the nasal tip or alar rim. During the follow-up period of 3-11 months, no tumor occurrence was observed.</p><p><strong>Conclusion: </strong>The reconstruction strategy reported in this study is a promising way in the repair of nasal tip soft tissue defect with little complication and satisfying outcomes.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"1253-1260"},"PeriodicalIF":1.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additive Therapeutic Effects of Topical Sirolimus Following Oral Propranolol Therapy for Kaposiform Hemangioendothelioma.","authors":"Bingyu Xiu, Zigang Xu, Zhe Xu, Bin Zhang, Li Wei, Lin Ma","doi":"10.2147/CCID.S520410","DOIUrl":"10.2147/CCID.S520410","url":null,"abstract":"<p><strong>Background: </strong>Kaposiform hemangioendothelioma (KHE) is a rare but aggressive vascular tumor, potentially life-threatening when associated with Kasabach-Merritt phenomenon (KMP). Oral sirolimus is effective but may cause systemic adverse effects in infants. Oral propranolol offers a safer alternative in early infancy, but its efficacy may plateau over time. Sequential topical sirolimus may enhance outcomes while minimizing systemic toxicity.</p><p><strong>Objective: </strong>To evaluate the additive therapeutic effect and safety of topical sirolimus in KHE patients with suboptimal response after oral propranolol.</p><p><strong>Methods: </strong>This retrospective study included five pediatric patients with cutaneous KHE treated at Beijing Children's Hospital from October 2018 to October 2022. All had received oral propranolol for ≥24 months and showed therapeutic plateau (tumor shrinkage ≤70%). They were subsequently treated with 0.1% topical sirolimus ointment twice daily for at least six months and followed for one year. Efficacy was assessed by Visual Analog Scale (VAS), Doppler ultrasound, and a four-grade evaluation system; safety was monitored throughout.</p><p><strong>Results: </strong>All patients showed significant improvement within 6-12 months (mean: 9.6 months), achieving Grade III or IV response. Doppler imaging revealed reduced or absent blood flow signals, and lesions nearly regressed in some cases. Symptoms such as pain and localized hyperthermia resolved, and skin appearance normalized. Two patients experienced mild local irritation; no systemic adverse effects or recurrences were observed.</p><p><strong>Conclusion: </strong>Sequential topical sirolimus following oral propranolol offers a safe and effective treatment strategy for KHE, especially after therapeutic plateau. It enhances efficacy, avoids systemic toxicity, and may accelerate lesion regression. Further large-scale studies are warranted to optimize individualized treatment protocols.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"1261-1267"},"PeriodicalIF":1.9,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12106589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recovery Effects of Oral Supplementation with Polar Lipid-Rich Wheat Extracts on Acute Telogen Effluvium: A Randomized Double-Blind Placebo-Controlled Study.","authors":"Vincenzo Nobile, Stéphanie Dudonné, Catherine Kern, Enza Cestone, Christine Garcia","doi":"10.2147/CCID.S521215","DOIUrl":"10.2147/CCID.S521215","url":null,"abstract":"<p><strong>Background: </strong>Acute telogen effluvium (aTE) is a transient condition characterized by an early entry of the hair into the telogen phase.</p><p><strong>Purpose: </strong>This clinical study aimed at demonstrating the efficacy of a standardized wheat polar lipid complex both in oil (WPLC-O) and in powder (WPLC-P) form in improving hair shedding.</p><p><strong>Subjects and methods: </strong>The study was carried out in 99 healthy women with aTE. Hair growth cycle related parameters (anagen/telogen hair), hair pull test, hair shaft mechanical properties (hair elongation at break) and hair growth were assessed at baseline and after 56 (D56) and/or 84 (D84) days of products use. These parameters were completed by the subject's self-assessment.</p><p><strong>Results: </strong>Telogen hair density was decreased by up to 26.9% and 24.2% while anagen density was increased by up to 10.3% and 10.8%, for WPLC-O and WPLC-P, respectively. These effects were significant compared with the placebo as early as within 56 days. These variations corresponded to an increase in the anagen/telogen ratio by up to 62.2% and 53.3% for WPLC-O and WPLC-P, respectively. Hair growth was also significantly increased in both active groups. At the end of the study the pull test was negative for aTE, exclusively in active treatment arms.</p><p><strong>Conclusion: </strong>Our findings demonstrated the efficacy of WPLC in both form in reducing hair shedding and in improving hair growth in women with aTE.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"1239-1251"},"PeriodicalIF":1.9,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Apremilast in Oncological Patients with Moderate-to-Severe Plaque Psoriasis: A 5 years Retrospective Observational Study.","authors":"Caterina Lanna, Antonia Rivieccio, Martina Vultaggio, Ruslana Gaeta Shumak, Francesco Maria Bonacci, Fabio Artosi, Cristiana Borselli, Gaetana Costanza, Luca Bianchi, Elena Campione","doi":"10.2147/CCID.S499658","DOIUrl":"10.2147/CCID.S499658","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis and psoriatic arthritis are chronic autoimmune inflammatory conditions frequently associated with a range of comorbidities, including oncological diseases. Managing these conditions in patients with a history of cancer requires careful consideration of treatment efficacy and safety. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, has shown promise in the treatment of psoriasis and psoriatic arthritis. However, data on its use in oncological patients remain limited.</p><p><strong>Methods: </strong>This retrospective observational study evaluated the efficacy and safety of Apremilast in 79 patients with a history of cancer who were treated for psoriasis and/or psoriatic arthritis over a period of approximately five years. Clinical outcomes were assessed using the Psoriasis Area Severity Index (PASI), Dermatology Life Quality Index (DLQI), and Visual Analog Scale for pain (PAIN VAS) to monitor disease severity, quality of life, and articular involvement, respectively. Regular oncological assessments were conducted concurrently with Apremilast therapy to ensure patient safety and identify potential interactions.</p><p><strong>Results: </strong>Over the five-year treatment period, significant improvements were observed in PASI, DLQI, and PAIN VAS scores, indicating effective management of both dermatological and articular symptoms. Patients reported enhanced quality of life and reduced pain levels, reflecting the therapeutic benefits of Apremilast. Oncological evaluations revealed no significant adverse interactions between Apremilast and the patients' cancer history or treatments, underscoring the drug's safety profile in this population.</p><p><strong>Conclusion: </strong>This study highlights the efficacy and safety of Apremilast as a treatment option for psoriasis and psoriatic arthritis in oncological patients. The findings support its role in improving disease outcomes and quality of life, emphasizing the importance of personalized treatment strategies in managing complex cases involving a history of cancer. Further research is warranted to validate these results in larger patient cohorts.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"1231-1238"},"PeriodicalIF":1.9,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent Eosinophilic Fasciitis: The First Case Report.","authors":"Gai Ge, Fei Su, Hui Chen, Bin Hu, Jinbo Chen","doi":"10.2147/CCID.S518593","DOIUrl":"10.2147/CCID.S518593","url":null,"abstract":"<p><p>Eosinophilic fasciitis (EF) is a rare sclerodermic form disease characterized by upper and lower limb edema. Here, we present a rare recurrent EF. A 57-year-old man presented to dermatology outpatient with skin induration on his both limbs. A diagnose of EF was made 12 years ago. According to swelling induration, eosinophilia >0.5 × 10⁹/l, hyperintense fascia on MRI T2-weighted images, and fascial thickening with accumulation of lymphocytes and macrophages with eosinophilic infiltration, he was diagnosed as EF. Patient was successfully treated with oral prednisone and methotrexate (MTX). To our knowledge, this is the first report of recurrent EF during the last twenty years. We report this case to analyze the reasons for recurrent EF and review-related literature to further provide experience for the diagnosis and treatment of recurrent EF.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"1219-1223"},"PeriodicalIF":1.9,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment with a Combination of Oral and Topical Glycyrrhizinic Acid in an Immunocompetent Anogenital Warts Patient.","authors":"Pati Aji Achdiat, Safira Mitayani Pranata, Retno Hesty Maharani","doi":"10.2147/CCID.S515703","DOIUrl":"10.2147/CCID.S515703","url":null,"abstract":"<p><strong>Introduction: </strong>Anogenital warts (AGW) are benign proliferative diseases caused by human papillomaviruses (HPV), characterized by verrucous papules on the genital or anal region In line with these findings, the prevalence of AGW is high among males and increasing in Indonesia, and most patients seek treatment because warts are cosmetically disfiguring and itchy. Self-applied treatments may cause local adverse effects such as irritation or burning. Oral and topical administration of glycyrrhizinic acid (Gly) has been observed to have antiviral and anticancer properties.</p><p><strong>Case report: </strong>A 21-year-old immunocompetent patient presented with multiple verrucous lesions on the anal region. Histopathological results showed condyloma acuminate type of AGW, and polymerase chain reaction results showed HPV type 11. The patient was treated with a combination of 10 mL oral Gly thrice daily and self-applied topical Gly three to four pumps thrice daily. The lesions gradually resolved after the first week of the combination of treatments. Subsequently, after 12 weeks of treatment, the wart decreased to one verrucous lesion, and the patient showed no adverse effects.</p><p><strong>Discussion: </strong>Gly exhibited broad-spectrum antiviral effects against HPV, herpesviruses, hepatitis viruses, and others. Oral and topical applications are considered safer than intravenous administration. Previous studies on Gly-based topical treatment showed effectiveness in the treatment of AGW with minimal side effects. Oral Gly supplements also have been found to enhance immune response and aid in HPV treatment, particularly when combined with topical Gly. According to the results, a combination of oral and topical Gly leads to high HPV clearance rates, making it a promising non-invasive treatment option.</p><p><strong>Conclusion: </strong>The combination of topical and oral Gly appears to be a promising self-applied treatment of AGW. However, the potential for recurrence warrants further observation and long-term follow-up studies.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"1225-1230"},"PeriodicalIF":1.9,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous Granuloma Resulting from Mixed Infection with <i>Mycobacterium marinum</i> and <i>Candida metapsilosis</i>: A Case Report of Successful Treatment.","authors":"Jing Li, Yinggai Song, Xiao Liu, Jing Pan","doi":"10.2147/CCID.S520618","DOIUrl":"10.2147/CCID.S520618","url":null,"abstract":"<p><strong>Background: </strong><i>Mycobacterium marinum</i> and <i>Candida metapsilosis</i> are rare pathogens that cause chronic cutaneous and soft tissue infections. Although molecular technologies have improved their diagnosis, both diseases are challenging to treat. Here, we describe the first case of cutaneous granuloma caused by concurrent <i>M. marinum</i> and <i>C. metapsilosis</i> infections.</p><p><strong>Case presentation: </strong>A 67-year-old male patient presented with a one-year history of painful erythematous nodules on his left ring finger after a fish stabbing. He was apparently immunocompetent and received no immunosuppressive treatment. Histopathological examination revealed infectious granuloma. Positive cultures for mycobacteria and fungi, along with molecular testing, confirmed the mixed infection with <i>M. marinum</i> and <i>C. metapsilosis</i>. Considering his old age and hepatitis B core antibody, we initiated treatment with oral clarithromycin, topical sulfadiazine silver cream (SSC), and topical nifuratel nystatin gel (NNG). Owing to adverse events, the course of clarithromycin was limited to ten days. Nonetheless, a three-month regimen of continuous topical SSC and NNG led to the complete recovery of his lesions without recurrence.</p><p><strong>Conclusion: </strong>This is the first reported case of mixed infection with <i>M. marinum</i> and <i>C. metapsilosis</i>. The combination therapy with 10-day oral clarithromycin treatment and 3-month topical SSC and NNG successfully treated superficial infections caused by these two distinct pathogens. This case could offer a viable alternative for patients unable to endure prolonged systemic therapy. Further studies are required to verify its efficacy.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"1213-1218"},"PeriodicalIF":1.9,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facial Structures and Their Impact on Visual Perception of Beauty and Youthfulness: Parallelism.","authors":"Raul Banegas, Maria Cecilia Miksa, Ery Ayelen Ko","doi":"10.2147/CCID.S513424","DOIUrl":"10.2147/CCID.S513424","url":null,"abstract":"","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"1207-1211"},"PeriodicalIF":1.9,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment of Cutaneous Foreign Body Granuloma with JAK Inhibitor Abrocitinib and Prednisone: A Case Report.","authors":"Jingqiu Fu, Wen Luo, Ping Wang, Weiwei Wu, Jiejie Lu","doi":"10.2147/CCID.S522469","DOIUrl":"10.2147/CCID.S522469","url":null,"abstract":"<p><strong>Background: </strong>Foreign body granuloma (FBG) formation is linked to chronic persistent cutaneous inflammation, representing a severe delayed complication characterized histologically by infiltration of multinucleated giant cells and aggregation of lymphocytes. In filler-induced FBG following cosmetic injections, implanted materials represent a key driver of sustained inflammatory responses. Achieving complete resolution remains challenging, with current therapeutic outcomes for FBG being suboptimal. Emerging evidence suggests that Janus kinase (JAK) inhibitors may constitute a promising therapeutic strategy for refractory granulomatous conditions.</p><p><strong>Objective: </strong>This case report describes the successful management of FBG using JAK inhibitors and synthesizes existing literature to evaluate the efficacy, safety, and potential mechanisms of abrocitinib in treating filler-induced cutaneous FBG.</p><p><strong>Methods: </strong>We present a case of post-filler FBG that presents with multiple smooth-surfaced, hemispherical lesions (3-5 mm in diameter) distributed across the entire facial region. The patient was treated with oral abrocitinib (100 mg daily) and prednisone (30 mg daily, tapered over 9 weeks). Clinical outcomes were assessed weekly for 13 weeks through serial clinical photography, dermoscopy, reflectance confocal microscopy, and multispectral imaging. Adverse events, including rash exacerbation, vomiting, dizziness, and fever, were systematically monitored. A comprehensive literature review was conducted to elucidate JAK inhibitors' therapeutic rationale in filler-associated FBG.</p><p><strong>Results: </strong>The patient achieved complete granuloma resolution within 13 weeks following failed corticosteroid monotherapy. No treatment-related adverse effects were observed during the one-month follow-up period, supporting the favorable safety profile of this therapeutic approach.</p><p><strong>Conclusion: </strong>This report provides preliminary evidence for JAK inhibitors' efficacy in managing refractory filler-induced FBG. Large-scale controlled trials are warranted to validate long-term safety and therapeutic benefits.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"1199-1206"},"PeriodicalIF":1.9,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12094822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab for Atopic Dermatitis with Twenty-Nail Dystrophy: A Case Report.","authors":"Ji Li, Duo Zhang, Shuying Dong, Lili Zhu, Xiaodong Li, Yang Han","doi":"10.2147/CCID.S524384","DOIUrl":"10.2147/CCID.S524384","url":null,"abstract":"<p><p>Atopic dermatitis (AD) typically presents with cutaneous symptoms, but nail changes, particularly twenty-nail dystrophy (TND), are often overlooked. We report a case of a 40-year-old woman with a 3-year history of eczematous erythema and pruritus around the nails, accompanied by nail deformities. She had elevated serum IgE levels (2250 IU/mL) and dermatoscopic findings of thickened yellowish nails with splinter hemorrhages. Diagnosed with AD and TND, she received dupilumab after failing conventional treatments. Within 2 weeks, she experienced significant itch relief, and by 5 months, nearly complete nail recovery was observed, with serum IgE levels decreasing to 823 IU/mL. This case highlights the importance of recognizing nail involvement in AD, suggesting that periungual eczema and TND may represent a distinct phenotype. Dupilumab shows promise as an effective treatment for this condition, warranting further research.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"1187-1190"},"PeriodicalIF":1.9,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}